OncoMatch/Clinical Trials/NCT06511037
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
Is NCT06511037 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging for gastrointestinal cancer.
Treatment: Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging — This is a pilot, single-arm, open label study to evaluate the ability of CYTALUX™ (pafolacianine) to help identify cancerous lesions in subjects with gastrointestinal cancers and peritoneal carcinomatosis during cytoreductive surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Ovarian Cancer
Prior therapy
Cannot have received: pafolacianine (cytalux, pafolacianine)
Cannot have received: investigational agent
Lab requirements
Kidney function
eGFR <50 mL/min/1.73m2 excluded
Liver function
ALT, AST, ALP, or total bilirubin >3x ULN excluded
Impaired renal function defined as eGFR <50 mL/min/1.73m2; Impaired liver function defined as values >3x the upper limit of normal (ULN) for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin; Clinically significant abnormalities on ECG
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Chao Family Comprehensive Cancer Center, University of California, Irvine · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify